.png){kind=icon}
.png){kind=icon}
Return
sGC stimulator BAY 41-8543 improves survival and ventricular function in a rat model of doxorubicin-induced cardiomyopathy with nephrotic syndrome
.png){kind=icon}
OA
AI
O
P
S
Z
M
O
K
S
S
B
M
L
P
L
M
DOI：10.1111/bph.70608.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Anthracyclines such as doxorubicin (DOXO) remain a cornerstone of cancer therapy but are associated with a high risk of cardiotoxicity and subsequent heart failure (HF). Impairment of NO/soluble guanylyl cyclase (sGC)/cGMP pathway has been reported in anthracycline-induced cardiomyopathy. This raises the hypothesis that increasing cGMP by sGC stimulation could preserve cardiac function even after HF has developed. This study aimed to evaluate the long-term effects of treatment with sGC stimulator BAY 41-8543 in a model of DOXO-induced HF with nephrotic syndrome in hypertensive rats.
Keywords:
anthracycline cardiotoxicity
doxorubicin
NO/sGC/cGMP pathway
sGC stimulator
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
7.7
Papers:
1.4W
Citations:
3.7W
Organization
Cited Papers